Early Life and Education
Christian Angermayer was born on April 26, 1978, in Wiesau, Germany. In 1998, he began studying biochemistry at the University of Bayreuth. During this time, he met professors Roland Kreutzer and Stefan Limmer. They were working on a new gene-targeting method called RNA interference. In 2000, Angermayer and the professors co-founded Ribopharma AG. Though Angermayer only held a minority stake, Ribopharma received backing from the German government, allowing him to drop out of college.
Rise to Success
Angermayer's career took off when Ribopharma merged with Alnylam Pharmaceuticals in 2003, which later went public. He became a multimillionaire by age 25. Since then, he has been involved in numerous successful companies, raising over $2 billion for his portfolio companies and participating in over 50 successful IPO and M&A transactions. He is the founder of Apeiron Investment Group, a family office and merchant banking business, and co-founder of atai Life Sciences, a biotechnology company focused on mental health treatments. Angermayer's business interests include biotechnology, psychedelics-based medicine, longevity research, financial technology, cryptocurrency, and emerging technologies.
Key Business Strategies
Angermayer's investment strategy involves a global multi-strategy investment approach. Apeiron Investment Group invests across the entire company lifecycle, from seed/startup investments to large-scale growth rounds and investments into listed companies. His focus is on long-term value creation and strategic partnerships. He has been described as a pioneer in the cryptocurrency industry. He is also the co-founder of the Enhanced Games, a sporting event where performance enhancements are permitted.
Philanthropy
While the exact amounts of Angermayer's philanthropy aren't explicitly detailed, he is known to be involved in medical philanthropy. Furthermore, Angermayer supports various initiatives through Apeiron Investment Group, a family office and merchant banking business.
